IP
GYRE icon

Intellectus Partners’s Gyre Therapeutics GYRE Stock Holding History

Intellectus Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-9
Closed -$713 – 590
2018
Q2 		$1K Hold
9
– – ﹤0.01% 575
2018
Q1 		$2K Hold
9
– – ﹤0.01% 565
2017
Q4 		$1K Hold
9
– – ﹤0.01% 599
2017
Q3 		$0 Hold
9
– – ﹤0.01% 787
2017
Q2 		$0 Hold
9
– – ﹤0.01% 776
2017
Q1 		$1K Sell
9
-830
-99% -$48.5K ﹤0.01% 670
2016
Q4 		$61K Buy
+839
New +$75.5K 0.03% 288

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Intellectus Partners's GYRE Position: Q3 2018 in Review

Intellectus Partners sold out of Gyre Therapeutics (GYRE) in Q3 2018, closing a stake of 9 shares — an estimated $713 sold.

Intellectus Partners first reported a position in GYRE in Q4 2016 and held it in 7 quarters. The position peaked at $61K in Q4 2016. 70 funds tracked by Wall St. Rank hold GYRE as of Q3 2018.

  • Intellectus Partners reported no remaining Gyre Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Intellectus Partners sold 9 Gyre Therapeutics shares in Q3 2018, an estimated $713.
  • Intellectus Partners first reported a position in Gyre Therapeutics in Q4 2016 and held it in 7 quarters.
  • Intellectus Partners's Gyre Therapeutics position peaked at $61K in Q4 2016.
  • 70 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2018.

Based on Intellectus Partners's 13F filing for Q3 2018, filed 15 Nov 2018.